FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Nashington,	D.C. 20549
-------------	------------

STATEMENT	OF CHAN	GES IN I	BENEFICIAL	OWNERSHIP

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden 0.5 hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*  Jain Vivek				2. Issuer Name and Ticker or Trading Symbol ICU MEDICAL INC/DE [ ICUI ]									Relationship of Reporting Person(s) to Issuer (Check all applicable)						
Jaiii VI	<u>vek</u>				<u> </u>									X	Directo			10% Ow Other (s	
(Last) (First) (Middle)					3. Date of Earliest Transaction (Month/Day/Year) 05/17/2023								X	helow) be			below)	pecity	
951 CALLE AMANECER													Chairman and CEO						
(0)				4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street) SAN	C.	٨	92673											X		,		orting Perso	
CLEME	NTE C.	A	926/3												Form fi Persor		e thar	One Repor	ting
(City)	(S	tate)	(Zip)		Ru	le 1	.0b5-:	1(c)	Transa	ctic	n Ind	lication	1						
						Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.								d to					
		Tab	le I - Nor	n-Deriv	ative	Sec	urities	A C	quired, D	ispo	osed o	of, or Be	nefici	ally	Owned	ł			
1. Title of Security (Instr. 3)  2. Trans: Date (Month/L				Execution Date,		Transaction Disposed Of (I Code (Instr. 5)			ties Acquired (A) o I Of (D) (Instr. 3, 4 a				es Fo ally (D) Following (I)	Form (D) o	orm: Direct ) or Indirect (Instr. 4)	7. Nature of Indirect Beneficial Ownership			
								Code	v	Amount	(A) or (D) P		е	Reported Transact (Instr. 3	ction(s)			(Instr. 4)	
		Т							uired, Dis , options						Owned				
1. Title of Derivative Security (Instr. 3)  2. Conversion or Exercise Price of Derivative Security  3. Transaction Date (Month/Day/Year)  (Month/Day/Year)  33. Deemed Execution Date (Month/Day/Year)  (Month/Day/Year)		Date,	Code (Instr.		n of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		S (1	. Price of Derivative Security Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)			
					Code	v	(A)	(D)	Date Exercisable		oiration	Title	Amour or Number of Shares	er					
Common Stock <sup>(1)</sup>	\$0.0 <sup>(2)</sup>	05/17/2023			A	-	14,615	(-,	(3)		15/2026	Common Stock	14,61	+	\$0.0	14,615	$\neg$	D	

## **Explanation of Responses:**

- 1. These securities are Restricted Stock Units.
- 2. There is neither a purchase price nor an exercise price for the Restricted Stock Units.
- 3. One third of the units subject to the award shall vest on each of the first, second, and third anniversaries of the grant date. These awards were legally granted on March 15, 2023 but were subject to shareholder approval on May 17, 2023.

By: Paula Darbyshire,

Attorney-in-fact For: Vivek

05/18/2023

<u>Jain</u>

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.